EDGE
Get a demo
Log In

Nanome

Extended Reality
Product stageSegments
Early
?
AR/VR platforms
?

Nanome offers a VR platform to visualize molecule structures and for remote collaboration in fields ranging from general chemistry, pharmaceutical drug discovery, and academic use cases. 

The platform enables chemists and biologists to interact with and modify 3D arrangements of molecules, communicate design ideas remotely, and visualize results. Additionally, the platform is used in university classrooms, allowing lecturers and students to interact with molecular structures in VR. The platform's virtual collaboration features include the hosting of public and private workspaces, alongside support of on-premise hosting done via Nanome, making it suitable for industries governed by stringent regulations, such as healthcare and pharmaceuticals. 

Other features include Nanome Stacks, a plugin infrastructure that connects scientific tools to its collaborative ideation environment, allowing for molecular structures to be imported onto the platform. In October 2023, the company introduced GenAI copilot ‘MARA’  capable of exploring, preparing, and rectifying various molecular file formats, as well as performing complex multi-step processes across different tools and databases. 

The company noted that Nanome could help shorten the average 12–18 month lead optimization timeline for new drugs, as per results of a case study. In October 2022, Nanome integrated its platform with the Meta Quest Pro.

Nanome offers freemium pricing plans. A free subscription is offered for personal use, with paid subscriptions including that for academic use, priced at USD 299 per year, clinical research priced at USD 5,000, and custom pricing for larger enterprises.

Key customers and partnerships

Key enterprise customers include Nimbus Therapeutics, Novartis, LifeArc, and Insilico Medicine. Notable universities using the platform include Harvard, Stanford, Berkeley, MiT, and Johns Hopkins. In March 2021, Nanome partnered with Discngine to improve structure-based drug design on its platform. Previous partnerships include that with Fujitsu (to bring its platform to the Japanese market in September 2020) and Science Exchange (to offer scientists on-demand access to Nanome’s blockchain and virtual reality technology in January 2018).

Competitors: None under coverage (Nanome offers a platform specialized in visualizing molecular structures for the healthcare industry.)

Extended Reality

Extended Reality

Key stats
Featured companies
236
Total funding (USD)
13.5 Bn
Total addressable market (USD)
100.4 Bn
Key competitors
 
Loading...
Loading...
Loading...
Loading...
Product Overview
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Product Metrics
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Company profile
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...

EDGE Insights

XR and MEP (Q4 2023): XR GenAI adoption accelerates alongside funding rebound

Recent Updates

Product updates
Oct 24, 2023
Nanome launches AI copilot 'MARA’ for molecular science
Extended Reality

Company Brief


HQ location:
9500 Gilman Dr San Diego CA USA
Founded year:
2016
Employees:
11-50
Total Funding:
USD 6.4 million
Last Funding
USD 3.0 million, Feb 2021

Funding


Investors


No investor data is available

Funding data are powered by Crunchbase
arrow
menuarrow
Click here to learn more
Get a demo

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.